PT - JOURNAL ARTICLE AU - Arnaud Tognetti AU - Evelina Thunell AU - Mats J. Olsson AU - Nina Greilert AU - Sebastian Havervall AU - Charlotte Thålin AU - Johan N. Lundström TI - High prevalence of olfactory disorders 18 months after contracting COVID-19 AID - 10.1101/2022.01.20.22269490 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.20.22269490 4099 - http://medrxiv.org/content/early/2022/01/20/2022.01.20.22269490.short 4100 - http://medrxiv.org/content/early/2022/01/20/2022.01.20.22269490.full AB - Reduced olfactory function is the symptom with the highest prevalence in COVID-19 with nearly 70% of individuals with COVID-19 experiencing partial or total loss of their sense of smell at some point during the disease. Recent reports suggest that more than 7 months after recovering from COVID-19, a large proportion of these individuals still have olfactory dysfunction of some form. To establish the prevalence of olfactory dysfunction 18 months and beyond, we tested 100 individuals with established COVID-19 in the first wave of the pandemic using psychophysical full-scale testing of smell and taste functions as well as assessments of parosmia. Participants were recruited from an ongoing study, comprising healthcare workers at a hospital in Stockholm, Sweden, that are regularly tested for SARS-CoV-2 IgG antibodies since the start of the pandemic in Sweden. To assess potential skewed recruitment of individuals with prior olfactory dysfunction and assess normal rate of dysfunctions in the used population, 44 SARS-CoV-2 IgG naïve individuals were also tested as a control group. One and a half year after COVID-19, more than one third of individuals recovered from COVID-19 demonstrated a clinical reduction in their sense of smell. Critically, nearly half of COVID-19-recovered individuals’ complaint about parosmia. Prevalence of gustatory dysfunction was, however, low (3%). In summary, a full 65% of individuals recovered from COVID-19 experience olfactory dysfunction of some form 18 months later. Given the amount of time since initial insult to the olfactory system, it is likely that these olfactory problems are permanent.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding provided by the Knut and Alice Wallenberg Foundation (KAW 2018.0152) and the Swedish Research Council (2021-06527).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained and all aspects of the study were approved by the Swedish Ethical Review Authority.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors